New drug combo targets Hard-to-Treat cancers in early trial
NCT ID NCT05111561
First seen Oct 31, 2025 · Last updated May 22, 2026 · Updated 36 times
Summary
This early-phase trial tests the safety and best dose of two oral drugs, ZEN003694 and binimetinib, taken together. It is for people with advanced solid tumors that have RAS pathway changes or triple-negative breast cancer that has spread or cannot be removed by surgery. The study aims to find a dose that is safe and may help shrink or stabilize the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE-NEGATIVE BREAST CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Boston Medical Center
Boston, Massachusetts, 02118, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of Texas Medical Branch
Galveston, Texas, 77555-0565, United States
Conditions
Explore the condition pages connected to this study.